pembrolizumab
merck
['keynote-716', 'melanoma']
dr s thoughts on #keynote-716. absolute risk reduction 8%, risk of toxicity is 17%. will this affect future treatment options? also need to consider cost. she reminds us we have effective therapy for recurrent disease! #melanoma #asco22 
Melanoma+Cell Therapy Oncologist @MSKCancerCenter| Cornell/DukeMed/ MGH IM/MSKCC Onc alum | FCOI: https://t.co/kwtet64Pe4